The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Healx has dosed the first subject in the open-label Phase II INSPIRE-NF1 trial to assess the efficacy and safety of HLX-1502 in individuals with neurofibromatosis type 1 (NF1), a rare genetic ...

RECKGIST score may predict recurrence in neurofibromatosis type 1 GISTs, potentially guiding treatment decisions, according ...

Conference taking place on March 27-29, 2025 in New Orleans -- -- CAGLA NeauxCancer Conference is a leading global forum in ...

Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.

Researchers have found in a nonrandomised pilot trial that selumetinib showed a reduction in cutaneous neurofibromatosis ...

together offer the potential to reshape the treatment of the rare disease neurofibromatosis type 1 (NF1). Healx, an artificial intelligence (AI)-based drug developer focused on treating rare ...

in patients with neurofibromatosis type 1 (NF1). NF1 is a debilitating rare genetic disorder that causes tumours to form along nerves, often manifesting in childhood. It affects approximately one ...

Discover a study that used the Skindex-29 assessment to evaluate emotional wellbeing during selumetinib cycles.